astrazeneca multi-target drug discovery collab, page-27

Ok, I'm obviously the only one getting too excited.

Attached is the chart from early 2012. If you look at the period ahead it looks very similar to our current chart. It was the beginning of a long run up to the mid 50's over 3 months. Here it wobbled around for ages until being put to bed by the failed IPO. The original run up was more of a valuation adjustment on no real news.

This cycle is consistent with ACL the lower chart is the 4 year monthly, which looks encouraging from where we are now at the lower end of what has traditionally being a strong rise over 3 to 6 months.